Synapse

← BJC Reports

Papers in BJC Reports

Page 2 · newest first

  1. Insomnia in early-stage breast cancer: time to listen, time to actBJC Reports · 2025
  2. Sleep hygiene in patients with early-stage breast cancer: a short reportBJC Reports · 2025
  3. A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2BJC Reports · 2025
  4. 'Is it my last Christmas?’ Using real-world data as a prompt to reflect on goal-concordant advanced lung cancer care—a retrospective, longitudinal studyBJC Reports · 2025
  5. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trialBJC Reports · 2025
  6. Tumor cell-intrinsic PD-1 regulates chemotherapy resistance in colorectal cancer cells by activating downstream MAPK signalingBJC Reports · 2025
  7. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trialBJC Reports · 2025
  8. Introduction of whole genome sequencing as NHS standard of care for glioma patients in two neurosurgical oncology centres: West MidlandsBJC Reports · 2025
  9. Cancer care disparities among patients with limited English proficiency: challenges and strategies for equityBJC Reports · 2025
  10. Bone marrow evaluation in neuroblastomas: bone marrow aspirates have little additional value over trephine biopsiesBJC Reports · 2025
  11. Somatic DICER1 pathogenic variants detected in a well-differentiated fetal lung adenocarcinoma diagnosed in a man with familial adenomatous polyposisBJC Reports · 2025
  12. Transcriptome profiling of uterine leiomyosarcomas identifies a leiomyoma-like expression pattern that indicates better survivalBJC Reports · 2025
  13. Medical comorbidities prognosticate survival in glioblastomaBJC Reports · 2025
  14. KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohortsBJC Reports · 2025
  15. Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situBJC Reports · 2025
  16. The transcription factor Blimp-1 is suppressed by SLAMF1 and drives Treg cell-mediated immune evasion in non-small cell lung cancerBJC Reports · 2025
  17. Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in NorwayBJC Reports · 2025
  18. Germline JAK2 R564Q variants presenting as hereditary thrombocytosis: case reportBJC Reports · 2025
  19. Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and CopperBJC Reports · 2025
  20. Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic reviewBJC Reports · 2025
  21. Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case seriesBJC Reports · 2025
  22. Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literatureBJC Reports · 2025
  23. Circulating tumour DNA assays in focus: highlights from ASCO 2025 for cliniciansBJC Reports · 2025
  24. Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancerBJC Reports · 2025
  25. Comment: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancerBJC Reports · 2025
  26. Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective studyBJC Reports · 2025
  27. Cataloguing and evaluating Irish health data resources for primary care cancer researchBJC Reports · 2025
  28. Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomniaBJC Reports · 2025
  29. Sex disparity in survival outcomes of advanced gastric adenocarcinomaBJC Reports · 2025
  30. A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trialsBJC Reports · 2025
  31. Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United KingdomBJC Reports · 2025
  32. Breast cancer survival in a rural setting in the Busoga Region of UgandaBJC Reports · 2025
  33. Long-term outcomes of consecutive patients of oropharyngeal cancer treated with radical radiotherapyBJC Reports · 2025
  34. Monoclonal antibody for phosphorylated TRIO Y2681 that helps predict prognosis of post-operative colorectal cancer patientsBJC Reports · 2025
  35. Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomyBJC Reports · 2025
  36. Interplay between AHR genotypes, lifestyle factors and adjuvant breast cancer treatments significantly impacts clinical outcome in a population-based cohortBJC Reports · 2025
  37. Patient derived cancer-associated fibroblasts from non-small cell lung cancer undergo phenotypic drift in cultureBJC Reports · 2025
  38. IL-6R expression is an independent prognostic factor in high-grade serous ovarian cancerBJC Reports · 2025
  39. Cancer risk after preeclampsia: a cohort study in two Nordic populationsTyöväentutkimus Vuosikirja · 2025
  40. Addressing financial toxicity for sustainable oncology care in the UKBJC Reports · 2025
  41. Cytoskeleton imaging of colorectal and lung cancer spheroids using light sheet microscopyBJC Reports · 2025
  42. Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case reportBJC Reports · 2025
  43. The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patientsBJC Reports · 2025
  44. Cancer prognosis and treatment results in patients with PTEN Hamartoma Tumour Syndrome (PHTS)—a European cohort studyBJC Reports · 2025
  45. Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancerBJC Reports · 2025
  46. Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohortBJC Reports · 2025
  47. B cells and tertiary lymphoid structures in cancer therapy responseBJC Reports · 2025
  48. Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classificationBJC Reports · 2025
  49. Stereotactic ablative radiotherapy for patients with hepatocellular carcinoma: analysis of post-treatment radiology and explant histologyBJC Reports · 2025
  50. Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodesBJC Reports · 2025